权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

A Minimally Invasive Platform to Target, Image, and Treat Head and Neck Cancer

用于定位、成像和治疗头颈癌的微创平台

基本信息

批准号：
10610322
负责人：
Hadiyah-Nicole Green
金额：
--
依托单位：
BIRMINGHAM VA MEDICAL CENTER
依托单位国家：
美国
项目类别：
财政年份：
2016
资助国家：
美国
起止时间：
2016-05-01 至 2022-09-30
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10610322
关键词：
Adjuvant Therapy Antibodies Antibody Specificity Antibody Therapy Binding Cell Death Chemoresistance Clinical Data Engineering Epidermal Growth Factor Receptor Fc Receptor Fluorescence Fluorescent Dyes Gold Head and Neck Cancer Image In Vitro Intravenous Kinetics Knowledge Label Lasers Longevity Malignant Neoplasms Mediating Methods Modality Modeling Mus Palliative Care Palpable Patients Performance Permeability Quality of life Recurrence Reporting Resistance Specificity Techniques Testing Therapeutic Time Tissue Sample Translating Translations Treatment Efficacy Treatment Protocols Tumor Volume United States Department of Veterans Affairs Veterans Xenograft Model absorption antibody conjugate base cancer cell cancer therapy cell killing cost experience fluorescence imaging human model human tissue improved in vivo in vivo Model minimally invasive nanoparticle nanoparticle delivery nanorod nanotherapy neoplastic cell novel overexpression patient population patient prognosis photothermal therapy public health relevance response side effect standard of care targeted delivery targeted imaging targeted treatment tumor

项目摘要

DESCRIPTION (provided by applicant): This proposal combines fluorescent imaging, active targeting, and subsequent photothermal treatment of malignant cells as an approach for treating head and neck cancers. The use of a near-infrared (NIR) laser enables us to take advantage of both the plasmon resonance absorption peak of gold nanorods (AuNRs), ~785 nm, as well as the absorption peak of the fluorescent dye, ~774 nm. We propose to label anti-EGFR antibodies, which target the over-expressed EGFR on malignant cells, with a fluorescent dye and conjugate them to AuNRs. This active targeting is expected to prove more efficient than previously reported approaches that relied solely on enhanced permeability and retention effects. Our preliminary results suggest that NIR photothermal treatment heated the AuNRs, excited fluorescence, killed approximately 90% of tumor cells in vitro, and provided a 40% reduction in tumor volume in vivo. To our knowledge, this is the first demonstration of a minimally invasive modality to combine tumor targeting and fluorescent imaging with a method to induce tumor regression in live mice. We aim to demonstrate that this multifunctional platform to target, image, and treat tumors is an improvement over current treatment regimens for Veterans suffering with head and neck cancer.